This study is a single-center, prospective, single-arm, exploratory clinical study (phase II exploratory trial). No parallel control group was established in the study, and all subjects who met the inclusion criteria underwent a uniform surgical treatment approach, namely, double-scope combined resection with mesenteric vascular preconditioning. The study aims to preliminarily evaluate the safety and effectiveness of this novel surgical strategy for the treatment of submucosal tumor at the gastroesophageal junction, and to provide data support for subsequent larger-scale controlled studies.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Conversion to open surgery rate
Timeframe: During surgery
Total operation time
Timeframe: During surgery
Number of endoscopic hemostasis procedures
Timeframe: The day of surgery
Endoscopic hemostasis time
Timeframe: The day of surgery (in minutes),up to 1440minutes (24hours)
Perioperative complication rate
Timeframe: Within 30 days after surgery
Postoperative peripheral white blood cell count
Timeframe: On the first and third days after surgery.
Adverse Events (AE)
Timeframe: within 30 days after surgery
Serious Adverse Event (SAE)
Timeframe: within 30 days after surgery